Suppr超能文献

新型取代靛类化合物的合成及激酶抑制活性

Synthesis and kinase inhibitory activity of novel substituted indigoids.

作者信息

Beauchard Anne, Laborie Hélène, Rouillard Hervé, Lozach Olivier, Ferandin Yoan, Le Guével Rémy, Guguen-Guillouzo Christiane, Meijer Laurent, Besson Thierry, Thiéry Valérie

机构信息

Université de La Rochelle, UMR CNRS 6250, LIENSs, Bât. Curie, Equipe Molécules à Activités Biologiques, Avenue Michel Crépeau, F-17042 La Rochelle, France.

出版信息

Bioorg Med Chem. 2009 Sep 1;17(17):6257-63. doi: 10.1016/j.bmc.2009.07.051. Epub 2009 Jul 25.

Abstract

The bis-indole indigoids are a promising protein kinase inhibitor scaffold to be further evaluated against the numerous human diseases that imply abnormal regulation of kinases including neurodegenerative disorders. In an effort to identify new pharmacological inhibitors of disease-relevant protein kinases with increased potency and selectivity, we designed, synthesized new 5,7-disubstituted or 6-substituted bis-indole derivatives. On the basis of our previous synthetic work, 22 selected compounds were tested on CDK1/cyclin B, CDK5/p25, DYRK1A, CK1, and GSK-3alpha/beta kinases, five kinases involved in Alzheimer's disease. Some of them were also evaluated for their cytotoxic and antiproliferative activities. 6-Nitro-3'-N-oxime-indirubin and 5-amino-3'-N-oxime-indirubin derivatives exhibited inhibitory activity in a submicromolar range against CDK1/cyclin B (0.18 and 0.1 microM, respectively), CK1 (0.6 microM and 0.13 microM) and GSK3 (0.04 microM and 0.36 microM).

摘要

双吲哚靛类化合物是一种很有前景的蛋白激酶抑制剂支架,有待针对包括神经退行性疾病在内的众多涉及激酶异常调节的人类疾病进行进一步评估。为了鉴定出具有更高效力和选择性的与疾病相关的蛋白激酶的新药理抑制剂,我们设计并合成了新的5,7-二取代或6-取代双吲哚衍生物。基于我们之前的合成工作,对22种选定的化合物进行了针对CDK1/细胞周期蛋白B、CDK5/p25、DYRK1A、CK1和GSK-3α/β激酶(参与阿尔茨海默病的五种激酶)的测试。其中一些化合物还进行了细胞毒性和抗增殖活性评估。6-硝基-3'-N-肟-靛玉红和5-氨基-3'-N-肟-靛玉红衍生物对CDK1/细胞周期蛋白B(分别为0.18和0.1微摩尔)、CK1(0.6微摩尔和0.13微摩尔)和GSK3(0.04微摩尔和0.36微摩尔)表现出亚微摩尔范围的抑制活性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验